Table 4. Meta-regression analysis of the effects of AFP, GP73, GPC3, GPC3 + AFP, GP73 + AFP and GPC3 + GP73 + AFP on diagnostic accuracy.

Variable	Coeff.	Std. Err.	P value	RDOR	95% CI
AFP
Year	–0.370	0.5679	0.5359	0.69	0.18–2.65
Assay type	0.375	0.8449	0.6706	1.45	0.20–10.73
No. of HCC and control	–0.307	0.5815	0.6136	0.74	0.19–2.91
GP73
Year	–0.360	0.8495	0.6825	0.70	0.10–4.95
Assay type	–1.043	1.1361	0.3856	0.35	0.03–4.84
No. of HCC and control	0.793	0.8943	0.4013	2.21	0.28–17.37
GPC3
Year	0.185	1.2937	0.8912	1.20	0.05–28.51
Assay type	–1.198	0.913	0.2374	0.30	0.03–2.82
No. of HCC and control	0.598	1.1207	0.6130	1.82	0.12–28.22
GPC3 + AFP
Year	–0.975	0.3496	0.0494	0.38	0.14–1.00
Assay type	–0.375	0.8218	0.6722	0.69	0.07–6.73
No. of HCC and control	–0.673	0.5654	0.3000	0.51	0.11–2.45
GP73 + AFP
Year	–0.145	0.5795	0.8122	0.86	0.26–3.84
Assay type	1.377	0.7724	0.1347	3.96	0.54–28.86
No. of HCC and control	–0.845	0.3867	0.0806	0.43	0.16–1.16
GPC3 + GP73 + AFP
Year	0.504	0.6542	0.4606	1.66	0.38–7.27
Assay type	1.079	0.9113	0.2667	2.94	0.37–23.12
No. of HCC and control	0.602	0.5149	0.2726	1.83	0.57–5.85

GP73, Golgi protein 73; GPC-3, Golgi protein glypican-3; AFP, alpha-fetoprotein; HCC, hepatocellular carcinoma; RDOR, ratio of diagnostic odds ratio.